GeneDx Q1 revenue misses estimates, cuts FY26 outlook

GeneDx Holdings

04/05/2026 21:19

Overview

Rare disease genomics firm's Q1 revenue grew 17% yr/yr, missing analyst expectations

Adjusted EPS for Q1 missed analyst expectations

Exome and genome test volumes rose 34% yr/yr, reflecting strong demand

Outlook

GeneDx lowers full-year 2026 revenue guidance to $475 mln-$490 mln from $540 mln-$555 mln

Company expects exome and genome volume growth of at least 30% for 2026

GeneDx projects adjusted gross margin of approximately 70% for full-year 2026

Result Drivers

VOLUME GROWTH - 34% yr/yr increase in exome and genome test volumes drove revenue growth, per CEO Katherine Stueland

SUSTAINED DEMAND - Company cited strong ongoing demand for exome and genome testing as a key factor in Q1 performance

Company press release: ID:nBw4FN6fXa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Miss
$102.30 mln
$112.96 mln (9 Analysts)
Q1 Adjusted EPS
Miss
-$0.28
-$0.01 (7 Analysts)
Q1 Adjusted Net Loss
$8.20 mln
Q1 Net Loss
$63.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the healthcare facilities & services peer group is "buy"

Wall Street's median 12-month price target for GeneDx Holdings Corp is $153.00, about 134% above its May 1 closing price of $65.38

The stock recently traded at 56 times the next 12-month earnings vs. a P/E of 143 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)